AMGN Amgen Inc.

-0.39  -0%
Previous Close 184.83
Open 184.6
Price To Book 10.38
Market Cap 112,496,537,188
Shares 609,935,682
Volume 2,264,689
Short Ratio
Av. Daily Volume 3,056,819

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2020.
Tezepelumab - NAVIGATOR
Approval announced May 21, 2018.
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
sNDA approval announced June 11, 2018.
Relapsed Multiple Myeloma
sBLA approval announced June 29, 2017.
Vectibix (Panitumumab)
Wild-Type RAS Metastatic Colorectal Cancer
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
Approved April 15, 2015.
Chronic Heart Failure
Approval announced May 17, 2018.
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Approval announced December 1, 2017.
Cardiovascular disease
sBLA approval announced January 5, 2017.
Multiple Myeloma
FDA approval announced October 1, 2018.
Multiple Myeloma
sNDA approved January 17, 2018.
Relapsed Multiple Myeloma
PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
Phase 3 data released January 24, 2019 - primary endpoint met.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
FDA approval announced June 13, 2019.
ABP 980 (Kanjinti; trastuzumab-anns)
Herceptin biosimilar
BLA filing announced December 17, 2018. Estimated PDUFA date December 16, 2019.
ABP 710
REMICADE biosimilar - rheumatoid arthritis
Approved February 7, 2017.
Secondary hyperparathyroidism (SHPT)
FDA Approval announced April 9, 2019.
EVENITY (Romosozumab)
Phase 3 enrolment to be completed 2Q 2019.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Second Phase 3 trial initiation announced February 21, 2019.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
AMG 420
Relapsed. Refractory (R/R) Multiple Myeloma (MM)
Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
AMG 330
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
FDA approval announced December 14, 2018.
Nplate (Romiplostim)
Immune Thrombocytopenia (Pediatric)
sNDA filing announced December 19, 2018. Estimated PDUFA date October 18, 2019.
Nplate (Romiplostim)
Immune thrombocytopenia (ITP)
Phase 3 data due 2019.
Multiple Myeloma
Phase 1 trial initiation announced February 20, 2019.
AMG 594
Healthy volunteers
Phase 1 data at ASCO June 3, 2019. 50% ORR in lung cancer patients. 90% SD.
AMG 510
Solid tumors

Latest News

  1. Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
  2. The 10 Biggest Biotech Stocks
  3. Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids
  4. This would be the worst-case scenario for health stocks, according to UBS
  5. Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
  6. Amgen (AMGN) Gains But Lags Market: What You Should Know
  7. The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
  8. Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership
  9. 3 Large-Cap Biotech Stocks to Buy for Massive Gains
  10. See what the IHS Markit Score report has to say about Amgen Inc.
  11. Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
  12. Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution
  13. Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
  14. Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) inhibitor AMG 510 at ASCO 2019
  15. Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019
  16. Amgen Drug Breaks New Ground
  17. FDA approves Lilly's migraine drug as first ever cluster headache treatment
  18. Amgen’s Good News on Lung Cancer Boosted Mirati Therapeutics. Here’s What Wall Street Is Saying.
  19. Sanofi loses German patent case against Amgen over cholesterol drug
  20. How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's?